CINCINNATI—Two recent studies by researchers at the University of Cincinnati (UC) bring to light interesting findings about the diagnosis of the rare lung disease Lymphangioleiomyomatosis ( LAM) and the reasons LAM patients participate in research studies.
Brent Kinder, MD, Frank McCormack, MD, and Jared Hagaman, MD, working with colleagues in the division of pulmonary, critical care and sleep medicine at UC, found that patients with LAM were more likely to participate in clinical trials because of a shared cause and a feeling of altruism, as opposed to personal benefit.